Agents targeting the Hedgehog pathway for pancreatic cancer treatment

Savita Bisht, Peter Brossart, Anirban Maitra, Georg Feldmann

Research output: Contribution to journalArticle

Abstract

Recent evidence has demonstrated that aberrant reactivation of the Hedgehog signaling pathway contributes to tumor initiation and progression in various human malignancies, including pancreatic cancer; therefore, the Hedgehog pathway has emerged as a promising novel therapeutic target. Initial translational studies conducted using cyclopamine, a small-molecule inhibitor of the Smoothened (SMO) component of the Hedgehog pathway, demonstrated that pharmacological blockade of aberrant Hedgehog signaling has the potential to inhibit tumor initiation, progression and metastatic spread. This concept has been corroborated using different compounds in various preclinical models of pancreatic cancer and other malignancies; several of these studies suggest possible therapeutic synergisms of Hedgehog inhibitors with established antineoplastic agents. This review provides a concise overview of translational studies assessing the use of Hedgehog inhibitors as novel therapeutic strategy for cancer, particularly pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)1387-1398
Number of pages12
JournalCurrent Opinion in Investigational Drugs
Volume11
Issue number12
StatePublished - Dec 2010

Fingerprint

Pancreatic Neoplasms
Neoplasms
Antineoplastic Agents
Therapeutics
Pharmacology

Keywords

  • Cyclopamine
  • glioma-associated oncogene homolog
  • Hedgehog signaling
  • mouse model
  • pancreatic cancer
  • small-molecule inhibitor
  • Smoothened hedgehog
  • Sonic hedgehog
  • therapeutic target
  • translational research

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Bisht, S., Brossart, P., Maitra, A., & Feldmann, G. (2010). Agents targeting the Hedgehog pathway for pancreatic cancer treatment. Current Opinion in Investigational Drugs, 11(12), 1387-1398.

Agents targeting the Hedgehog pathway for pancreatic cancer treatment. / Bisht, Savita; Brossart, Peter; Maitra, Anirban; Feldmann, Georg.

In: Current Opinion in Investigational Drugs, Vol. 11, No. 12, 12.2010, p. 1387-1398.

Research output: Contribution to journalArticle

Bisht, S, Brossart, P, Maitra, A & Feldmann, G 2010, 'Agents targeting the Hedgehog pathway for pancreatic cancer treatment', Current Opinion in Investigational Drugs, vol. 11, no. 12, pp. 1387-1398.
Bisht S, Brossart P, Maitra A, Feldmann G. Agents targeting the Hedgehog pathway for pancreatic cancer treatment. Current Opinion in Investigational Drugs. 2010 Dec;11(12):1387-1398.
Bisht, Savita ; Brossart, Peter ; Maitra, Anirban ; Feldmann, Georg. / Agents targeting the Hedgehog pathway for pancreatic cancer treatment. In: Current Opinion in Investigational Drugs. 2010 ; Vol. 11, No. 12. pp. 1387-1398.
@article{c7593a3b90c54ae9a7c6433b85f32b9d,
title = "Agents targeting the Hedgehog pathway for pancreatic cancer treatment",
abstract = "Recent evidence has demonstrated that aberrant reactivation of the Hedgehog signaling pathway contributes to tumor initiation and progression in various human malignancies, including pancreatic cancer; therefore, the Hedgehog pathway has emerged as a promising novel therapeutic target. Initial translational studies conducted using cyclopamine, a small-molecule inhibitor of the Smoothened (SMO) component of the Hedgehog pathway, demonstrated that pharmacological blockade of aberrant Hedgehog signaling has the potential to inhibit tumor initiation, progression and metastatic spread. This concept has been corroborated using different compounds in various preclinical models of pancreatic cancer and other malignancies; several of these studies suggest possible therapeutic synergisms of Hedgehog inhibitors with established antineoplastic agents. This review provides a concise overview of translational studies assessing the use of Hedgehog inhibitors as novel therapeutic strategy for cancer, particularly pancreatic cancer.",
keywords = "Cyclopamine, glioma-associated oncogene homolog, Hedgehog signaling, mouse model, pancreatic cancer, small-molecule inhibitor, Smoothened hedgehog, Sonic hedgehog, therapeutic target, translational research",
author = "Savita Bisht and Peter Brossart and Anirban Maitra and Georg Feldmann",
year = "2010",
month = "12",
language = "English (US)",
volume = "11",
pages = "1387--1398",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

TY - JOUR

T1 - Agents targeting the Hedgehog pathway for pancreatic cancer treatment

AU - Bisht, Savita

AU - Brossart, Peter

AU - Maitra, Anirban

AU - Feldmann, Georg

PY - 2010/12

Y1 - 2010/12

N2 - Recent evidence has demonstrated that aberrant reactivation of the Hedgehog signaling pathway contributes to tumor initiation and progression in various human malignancies, including pancreatic cancer; therefore, the Hedgehog pathway has emerged as a promising novel therapeutic target. Initial translational studies conducted using cyclopamine, a small-molecule inhibitor of the Smoothened (SMO) component of the Hedgehog pathway, demonstrated that pharmacological blockade of aberrant Hedgehog signaling has the potential to inhibit tumor initiation, progression and metastatic spread. This concept has been corroborated using different compounds in various preclinical models of pancreatic cancer and other malignancies; several of these studies suggest possible therapeutic synergisms of Hedgehog inhibitors with established antineoplastic agents. This review provides a concise overview of translational studies assessing the use of Hedgehog inhibitors as novel therapeutic strategy for cancer, particularly pancreatic cancer.

AB - Recent evidence has demonstrated that aberrant reactivation of the Hedgehog signaling pathway contributes to tumor initiation and progression in various human malignancies, including pancreatic cancer; therefore, the Hedgehog pathway has emerged as a promising novel therapeutic target. Initial translational studies conducted using cyclopamine, a small-molecule inhibitor of the Smoothened (SMO) component of the Hedgehog pathway, demonstrated that pharmacological blockade of aberrant Hedgehog signaling has the potential to inhibit tumor initiation, progression and metastatic spread. This concept has been corroborated using different compounds in various preclinical models of pancreatic cancer and other malignancies; several of these studies suggest possible therapeutic synergisms of Hedgehog inhibitors with established antineoplastic agents. This review provides a concise overview of translational studies assessing the use of Hedgehog inhibitors as novel therapeutic strategy for cancer, particularly pancreatic cancer.

KW - Cyclopamine

KW - glioma-associated oncogene homolog

KW - Hedgehog signaling

KW - mouse model

KW - pancreatic cancer

KW - small-molecule inhibitor

KW - Smoothened hedgehog

KW - Sonic hedgehog

KW - therapeutic target

KW - translational research

UR - http://www.scopus.com/inward/record.url?scp=79952768074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952768074&partnerID=8YFLogxK

M3 - Article

C2 - 21154121

AN - SCOPUS:79952768074

VL - 11

SP - 1387

EP - 1398

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 12

ER -